ArticleWorld journal of clinical oncology2011
IL-6/IL-6R as a potential key signaling pathway in prostate cancer development.
Article in World journal of clinical oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 120 citations in OpenAlex.
- Mechanical Stimuli-Induced Manipulation of Malignant Behavior in Bioprinted Cancer Microtissues via PI3K/NF-κB Activation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Obesogens in Prostate Cancer: An Endocrine and Metabolic Threat.Current obesity reports · 2026Review
- Inflammation Beyond the Prostate: The Role of Systemic Inflammatory Disorders in Prostate Carcinogenesis.Cureus · 2025Review
- Sleep deprivation impacts the immunological milieu of epididymis leading to low sperm quality in rats.Communications biology · 2025Article
- Article
- pSTAT3 Expression is Increased in Advanced Prostate Cancer in Post-Initiation of Androgen Deprivation Therapy.The Prostate · 2025Article
- The AC010247.2/miR-125b-5p axis triggers the malignant progression of acute myelocytic leukemia by IL-6R.Heliyon · 2024Article
- Dynamic Soluble IL-6R/Soluble gp130 Ratio as a Potential Indicator for the Prostate Malignancy Phenotype-A Multicenter Case-Control Study.Journal of personalized medicine · 2024Article
- Modulation of adipose-derived stem cell behavior by prostate pathology-associated plasma: insights from in vitro exposure.Scientific reports · 2024Article
- Interleukin-6 serves as a critical factor in various cancer progression and therapy.Medical oncology (Northwood, London, England) · 2024Review
- Article
- The Biochemical Effects of Silver Nanoparticles and Spirulina Extract on Experimentally Induced Prostatic Cancer in Rats.Biological trace element research · 2023Article
- Compressed Prostate Cancer Cells Decrease Osteoclast Activity While Enhancing Osteoblast Activity In Vitro.International journal of molecular sciences · 2023Article
- Review
- The tumor innate immune microenvironment in prostate cancer: an overview of soluble factors and cellular effectors.Exploration of targeted anti-tumor therapy · 2022Review
- IL-6 Signaling Link between Inflammatory Tumor Microenvironment and Prostatic Tumorigenesis.Analytical cellular pathology (Amsterdam) · 2022Review
- Three-Dimensional Growth of Prostate Cancer Cells Exposed to Simulated Microgravity.Frontiers in cell and developmental biology · 2022Article
- Proliferation of Mouse Prostate Cancer Cells Inflamed by Trichomonas vaginalis.The Korean journal of parasitology · 2021Article
- Nicaraven prevents the fast growth of inflamed tumors by an anti-inflammatory mechanism.Medical oncology (Northwood, London, England) · 2021Article
- Relationship between Circulating Lipids and Cytokines in Metastatic Castration-Resistant Prostate Cancer.Cancers · 2021Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin-6 (IL-6) is a pleiotropic cytokine involved in prostate regulation and in prostate cancer (PC) development/progression. IL-6 acts as a paracrine and autocrine growth stimulator in benign and tumor prostate cells. The levels of IL-6 and respective receptors are increased during prostate carcinogenesis and tumor progression. Several studies reported that increased serum and plasma IL-6 and soluble interleukin-6 receptor levels are associated with aggressiveness of the disease and are associated with a poor prognosis in PC patients. In PC treatment, patients diagnosed with advanced stages are frequently submitted to hormonal castration, although most patients will eventually fail this therapy and die from recurrent castration-resistant prostate cancer (CRPC). Therefore, it is important to understand the mechanisms involved in CRPC. Several pathways have been proposed to be involved in CRPC development, and their understanding will improve the way to more effective therapies. In fact, the prostate is known to be dependent, not exclusively, on androgens, but also on growth factors and cytokines. The signaling pathway mediated by IL-6 may be an alternative pathway in the CRPC phenotype acquisition and cancer progression, under androgen deprivation conditions. The principal goal of this review is to evaluate the role of IL-6 pathway signaling in human PC development and progression and discuss the interaction of this pathway with the androgen recepto pathway. Furthermore, we intend to evaluate the inclusion of IL-6 and its receptor levels as a putative new class of tumor biomarkers.The IL-6/IL-6R signaling pathway may be included as a putative molecular marker for aggressiveness in PC and it may be able to maintain tumor growth through the AR pathway under androgen-deprivation conditions. The importance of the IL-6/IL-6R pathway in regulation of PC cells makes it a good candidate for targeted therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.